Àííîòàöèÿ Ñ öåëüþ äåòàëüíîãî èçó÷åíèÿ ýëåêòðîôèçèîëîãè÷åñêèõ ýôôåêòîâ íîâîãî îòå÷åñòâåííîãî ïðåïàðàòà III êëàññà íèôåðèäèëà â ðàìêàõ ôàçû II êëèíè÷åñêîãî èñïûòàíèÿ îáñëåäîâàíî 25 ïàöèåíòîâ (18 ìóæ÷èí) â âîçðàñòå îò 19 äî 73 ëåò ñ äîêóìåíòèðîâàííûìè ïàðîêñèçìàìè íàäæåëóäî÷êîâûõ òàõèêàðäèé. | Annotation To study in detail electrophysiological properties of Niferidil, a novel III-class antiarrhythmic manufactured in Russia, 25 patients including 18 men aged 19 73 years with documented paroxysms of supraventricular tachycardia were examined during a Phase II clinical trial. |
Àâòîð Ìèðîíîâ, Í. Þ., Ãîëèöûí, Ñ. Ï., Ñîêîëîâ, Ñ. Ô., Ìàéêîâ, Å. Á., Øëåâêîâ, Í. Á., Þðè÷åâà, Þ. À., Ìàðååâ, Þ. Â., Ðîçåíøòðàóõ, Ë. Â., ×àçîâ, Å. È. | Íîìåðà è ðóáðèêè ÂÀ-¹70 îò 01/12/2012, ñòð. 5 /.. Îðèãèíàëüíûå èññëåäîâàíèÿ |